Abdominal Aortic Aneurysm Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Abdominal Aortic Aneurysm Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Abdominal Aortic Aneurysm, historical and forecasted epidemiology as well as the Abdominal Aortic Aneurysm market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Abdominal Aortic Aneurysm market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Abdominal Aortic Aneurysm Market Forecast
https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Abdominal Aortic Aneurysm Market Report:
• The Abdominal Aortic Aneurysm market size was valued approximately USD 1579.9 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, Shape Memory Medical Inc., a company specializing in shape memory polymers for endovascular applications, announced the first European patient enrollment in its AAA-SHAPE Pivotal Trial. This prospective, multicenter, randomized, open-label study aims to evaluate the safety and effectiveness of the IMPEDE-FX RapidFill® Device in enhancing abdominal aortic aneurysm (AAA) sac behavior during elective endovascular aneurysm repair (EVAR). The initial procedure was performed by Dr. Jan Heyligers, MD, PhD, and Professor Dr. Patrick Vriens, MD, PhD, vascular surgeons at Elisabeth TweeSteden Hospital in Tilburg, the Netherlands.
• In July 2024, Altamira Therapeutics' SemaPhore technology, combined with superoxide dismutase 2 (SOD2) mRNA, has effectively treated abdominal aortic aneurysm (AAA) in a mouse model. Preclinical data indicated a significant decrease in aortic dilation, a delay in rupture, and a notable improvement in survival rates compared to untreated controls among mice with AAA that received systemic treatment of SOD2 mRNA using peptide-based nanoparticles.
• The United States has the largest market share for Abdominal Aortic Aneurysm among the 7MM countries. In 2021, the market size for Abdominal Aortic Aneurysm in the US was USD 1,065.7 million.
• Japan has the smallest share of the Abdominal Aortic Aneurysm market among the 7MM countries, with a market size of USD 137.8 million in 2021, which is anticipated to grow by 2034.
• In January 2024, Arizona-headquartered Nectro Medical launched a Phase II/III clinical trial to assess the safety and effectiveness of its endovascular aneurysm stabilization treatment (Nectero EAST). Nectero EAST comprises a single-use endovascular system consisting of a dual-balloon delivery catheter and a stabilizing solution containing pentagalloyl glucose (PGG). When administered locally, PGG has the potential to bind to elastin and collagen, potentially reinforcing the aortic wall. Animal studies have demonstrated that PGG can impede the progression of abdominal aortic aneurysm (AAA).
• The total diagnosed prevalence of Abdominal Aortic Aneurysm in the 7MM was estimated at 1,641,380 cases in 2021, with expectations for an increase over the study period from 2020 to 2034.
• In 2021, the United States had an estimated 752,408 diagnosed prevalent cases of Abdominal Aortic Aneurysm, the highest among all 7MM countries.
• In 2021, the United States had the highest prevalence of Abdominal Aortic Aneurysm among the 7MM countries, with 8,773 cases.
• Within the European five countries, Germany had the highest prevalence of Abdominal Aortic Aneurysm, with 192,532 cases, followed by France with 138,193 cases, while Italy had the lowest prevalence among the EU-5, with 68,202 cases.
• Japan's total prevalence of Abdominal Aortic Aneurysm was estimated at 253,883 cases in 2021, with a projected decline over the forecast period from 2022 to 2034.
• Key Abdominal Aortic Aneurysm Companies: Endologix LLC, Lifetech Scientific, Lombard Medical, Merck Serono, AstraZeneca, Medtronic, RSPR Pharma AB, Nectero Medical LLC, Cardiatis, SA, Endologix LLC, RSPR Pharma AB, and others
• Key Abdominal Aortic Aneurysm Therapies: AFX® Endovascular ABDOMINAL AORTIC ANEURYSM System, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated Altura FEVAR Stent Graft, Nectero EAST System, Bifurcated MFM, Chimney EndoVascularAneurysm Sealing system, Ticagrelor, CRD007, and others
• The Abdominal Aortic Aneurysm epidemiology based on gender analyzed that Abdominal aortic aneurysms are more common in men
• The Abdominal Aortic Aneurysm market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Abdominal Aortic Aneurysm pipeline products will significantly revolutionize the Abdominal Aortic Aneurysm market dynamics.

Abdominal Aortic Aneurysm Overview
An Abdominal Aortic Aneurysm (AAA) is a bulging or enlargement of the aorta, the body's main artery, as it passes through the abdomen. This enlargement occurs when the artery wall weakens, causing it to expand and form a balloon-like structure. If the aneurysm grows too large, it risks rupturing, which can lead to severe internal bleeding and be life-threatening. Most AAAs develop slowly without symptoms but may sometimes cause back pain, a pulsating feeling in the abdomen, or abdominal pain. Regular screening and monitoring are important for early detection, and treatment options include lifestyle changes, medication, or surgery if the aneurysm is large or rapidly growing.

Get a Free sample for the Abdominal Aortic Aneurysm Market Report:
https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Abdominal Aortic Aneurysm Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Abdominal Aortic Aneurysm Epidemiology Segmentation:
The Abdominal Aortic Aneurysm market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Abdominal Aortic Aneurysm
• Prevalent Cases of Abdominal Aortic Aneurysm by severity
• Gender-specific Prevalence of Abdominal Aortic Aneurysm
• Diagnosed Cases of Episodic and Chronic Abdominal Aortic Aneurysm

Download the report to understand which factors are driving Abdominal Aortic Aneurysm epidemiology trends @ Abdominal Aortic Aneurysm Epidemiology Forecast
https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Abdominal Aortic Aneurysm Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Abdominal Aortic Aneurysm market or expected to get launched during the study period. The analysis covers Abdominal Aortic Aneurysm market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Abdominal Aortic Aneurysm Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Abdominal Aortic Aneurysm Therapies and Key Companies
• AFX® Endovascular ABDOMINAL AORTIC ANEURYSM System: Endologix LLC
• Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific
• Fenestrated Altura FEVAR Stent Graft: Lombard Medical
• Nectero EAST System: Nectero Medical LLC
• BifurcatedMFM: Cardiatis, SA
• Chimney EndoVascularAneurysm Sealing system: Endologix LLC
• Ticagrelor: Nectero Medical LLC
• CRD007: RSPR Pharma AB

To know more about Abdominal Aortic Aneurysm companies working in the treatment market, visit @ Abdominal Aortic Aneurysm Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Abdominal Aortic Aneurysm Market Strengths
• This condition is present in ≈2% of the elderly population,with ≈150 000 new cases diagnosed each year, and the incidence is increasing.
• In the last few years, all major aortic endograft companies have developed renewed models of grafts and/or delivery systems to cope with difficult anatomies and guarantee better delivery, more precise deployment, and improved performance.

Abdominal Aortic Aneurysm Market Opportunities
• Increasing geriatric population base and prevalence of AAA disease in the western countries provides a lucrative opportunity for the market.
• Increasing efforts to develop and discover drugs and devices that could potentially treat the disease

Scope of the Abdominal Aortic Aneurysm Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Abdominal Aortic Aneurysm Companies: Endologix LLC, Lifetech Scientific, Lombard Medical, Merck Serono, AstraZeneca, Medtronic, RSPR Pharma AB, Nectero Medical LLC, Cardiatis, SA, Endologix LLC, RSPR Pharma AB, and others
• Key Abdominal Aortic Aneurysm Therapies: AFX® Endovascular ABDOMINAL AORTIC ANEURYSM System, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated Altura FEVAR Stent Graft, Nectero EAST System, Bifurcated MFM, Chimney EndoVascularAneurysm Sealing system, Ticagrelor, CRD007, and others
• Abdominal Aortic Aneurysm Therapeutic Assessment: Abdominal Aortic Aneurysm current marketed and Abdominal Aortic Aneurysm emerging therapies
• Abdominal Aortic Aneurysm Market Dynamics: Abdominal Aortic Aneurysm market drivers and Abdominal Aortic Aneurysm market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Abdominal Aortic Aneurysm Unmet Needs, KOL's views, Analyst's views, Abdominal Aortic Aneurysm Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.